Description
Vardenafilisacentrally-actingphosphodiesterase5(PDE5)inhibitorthatisclinicallyusedtotreaterectiledysfunction.VardenafilalsoexhibitsantioxidativeandantihypertensiveactivitiesandshowssomepotentialforsynergisticchemotherapeuticABIlitythroughitsmodulationofcGMP-NOsignaling.ThiscompoundincreasesexpressionofNOandeNOSaswellasactivityofsuperoxidedismutase,decreasingoxidativestress,pulmonaryvascularresistance,andrightventricularhypertrophyandincreasingcardiacoutputinanimalmodelsofpulmonaryarterialhypertension(PAH).Vardenafildecreasesproteinuriaandglomerulardamageinanimalmodelsofdiabeticnephropathy-inducedcGMPpathwaydysfunction.Incellularmodels,vardenafildecreasessecretionofIL-8andexpressionofoxidativeLDLR(LOX-1),suggestingpotentialbenefitinthetreatmentofbenignprostatichyperplasia/lowurinarytractsyndrome(BPH/LUTS).
References
VignozziL,GacciM,CellaiI,etal.PDE5inhibitorsbluntinflammationinhumanBPH:apotentialmechanismofactionforPDE5inhibitorsinLUTS.Prostate.2013Sep;73(13):1391-402.PMID:23765639.
FanYF,ZhangR,JiangX,etal.Thephosphodiesterase-5inhibitorvardenafilreducesoxidativestresswhilereversingpulmonaryarterialhypertension.CardiovascRes.2013Aug1;99(3):395-403.PMID:23650288.
FangL,RadovitsT,SzabóG,etal.Selectivephosphodiesterase-5(PDE-5)inhibitorvardenafilamelioratesrenaldamageintype1diabeticratsbyrestoringcyclic3",5"guanosinemonophosphate(cGMP)levelinpodocytes.NephrolDialTransplant.2013Jul;28(7):1751-61.PMID:23203993
ZhuB,StradaSJ.ThenovelfunctionsofcGMP-specificphosphodiesterase5anditsinhibitorsincarcinomacellsandpulmonary/cardiovascularvessels.CurrTopMedChem.2007;7(4):437-54.PMID:17305584.
LauLC,AdaikanPG.Mechanismsofdirectrelaxanteffectofsildenafil,tadalafilandvardenafiloncorpuscavernosum.EurJPharmacol.2006Jul17;541(3):184-90.PMID:16777087.
